Tag Archives: Leah R. Cann

Miragen Therapeutics Inc (MGEN) Receives a Buy from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Miragen Therapeutics Inc (MGEN – Research Report), with a price target of $19. The company’s shares opened today at $3.53. Cann observed: “The data presented

CTI BioPharma (CTIC) Gets a Buy Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on CTI BioPharma (CTIC – Research Report), with a price target of $4. The company’s shares closed yesterday at $0.84, close to its 52-week low of

Oppenheimer Thinks Constellation Pharmaceuticals Inc’s Stock is Going to Recover

In a report released today, Leah R. Cann from Oppenheimer initiated coverage with a Buy rating on Constellation Pharmaceuticals Inc (CNST – Research Report) and a price target of $21. The company’s shares closed yesterday at $5.80, close to its

Seattle Genetics (SGEN) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Seattle Genetics (SGEN – Research Report) today. The company’s shares opened today at $63.95. Cann noted: “Adcetris, Seattle Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or

Analysts Are Bullish on These Healthcare Stocks: Celgene (CELG), Global Blood Therapeutics (GBT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celgene (CELG – Research Report), Global Blood Therapeutics (GBT – Research Report) and RedHill Biopharma (RDHL – Research Report) with bullish sentiments.

MEI Pharma (MEIP) Gets a Buy Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on MEI Pharma (MEIP – Research Report), with a price target of $7.50. The company’s shares closed on Friday at $2.88. Cann commented: “Preclinical data for